iconoclast - It makes sense to me that the placebo MACE rate would be lower in our trial as the standard of care continually increases, at least in theory. This trial started Nov 11 2015 so was designed in the year before that based on trial data from trials that had wrapped up in the 2 years prior to that. Those trials were designed a year prior to them starting and probably lasted about as long as ours. So when we look at it from a SOC point of view, what drugs are they using today that have improved the patients ability to slow the rate of 3 point MACE that have become available over the last 9 years. Not being a Dr. I can only think of a few, PCSK9's, SGLT2's and some beta blockers. Putting all of the available drugs together it would seem reasonable to me that the placebo group in our trial would have a better experience than the placebo group in previous trials.

tada